Recursion Pharmaceuticals (RXRX) Current Assets (2020 - 2026)

Recursion Pharmaceuticals has reported Current Assets for 7 years, with the latest figure at $709.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 21.47% year-over-year to $709.6 million; the trailing twelve-month figure through Mar 2026 stood at $709.6 million (up 21.47% YoY), and the FY2025 full-year result was $812.8 million, up 13.8% from the prior year.
• Current Assets for Q1 2026 stood at $709.6 million, down from $812.8 million in the prior quarter.
• The five-year high for Current Assets was $812.8 million in Q4 2025, with the low at $343.6 million in Q1 2024.
• Historically, Current Assets has averaged $555.9 million across 5 years, with a median of $546.0 million in 2022.
• Annual changes were most pronounced in 2022 — Current Assets jumped 179.26% — and 2024, when it sank 30.18%.
• Recursion Pharmaceuticals' Current Assets stood at $569.8 million in 2022, then dropped by 23.11% to $438.1 million in 2023, then jumped by 63.02% to $714.3 million in 2024, then advanced by 13.8% to $812.8 million in 2025, then dropped by 12.71% to $709.6 million in 2026.
• The last three Current Assets figures came in at $709.6 million (Q1 2026), $812.8 million (Q4 2025), and $714.1 million (Q3 2025), per Business Quant data.